Cancer Statistics, 2021.
Reads0
Chats0
TLDR
In the United States, the cancer death rate has dropped continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment as mentioned in this paper.Abstract:
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.read more
Citations
More filters
Journal ArticleDOI
Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020.
TL;DR: China is undergoing cancer transition with an increasing burden of lung cancer, gastrointestinal cancer, and breast cancers, and the burden of breast cancer is increasing globally.
Journal ArticleDOI
Cancer treatment and survivorship statistics, 2022
Kimberly D. Miller,Leticia Nogueira,Theresa P Devasia,Angela B. Mariotto,K. Robin Yabroff,Ahmedin Jemal,Joan L. Kramer,Rebecca L. Siegel +7 more
TL;DR: Estimation of cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries, vital statistics from the Centers for Disease Control and Prevention’s National Center for Health Statistics, and population projections from the US Census Bureau finds that more than 18 million Americans with a history of cancer were alive on January 1, 2022.
Journal ArticleDOI
Pancreatic Cancer: A Review
TL;DR: In this article, a multidisciplinary management approach is recommended for PDAC patients, which includes a multi-agent chemotherapy regimens, including FOLFIRINOX, gemcitabine/nab-paclitaxel, and nanoliposomal irinotecan/fluorouracil.
Journal ArticleDOI
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Jaffer A. Ajani,Thomas A. D'Amico,David J. Bentrem,Joseph Chao,David Cooke,Carlos U. Corvera,Prajnan Das,Peter C. Enzinger,Thomas Enzler,Paul T. Fanta,Farhood Farjah,Hans Gerdes,C. Michael Gibson,Steven N. Hochwald,Wayne L. Hofstetter,David H. Ilson,Rajesh N. Keswani,Sunnie Kim,Lawrence Kleinberg,Samuel J. Klempner,Jill Lacy,Quan P. Ly,Kristina A. Matkowskyj,Michael McNamara,Mary F. Mulcahy,Darryl Alan Outlaw,Haeseong Park,Kyle A. Perry,Jose M. Pimiento,George A. Poultsides,Scott I. Reznik,Robert Ross,Vivian E. Strong,Stacey Su,Hanlin L. Wang,Georgia L. Wiesner,Christopher G. Willett,Danny Yakoub,Harry H. Yoon,Nicole R. McMillian,Lenora A. Pluchino +40 more
TL;DR: Palliative management, which may include systemic therapy, chemoradiation, and/or best supportive care, is recommended for all patients with unresectable or metastatic cancer.
Journal ArticleDOI
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S. Ettinger,Douglas E. Wood,Dara L. Aisner,Wallace Akerley,Jessica Bauman,Ankit Bharat,Debora S. Bruno,Joe Y. Chang,Lucian R. Chirieac,Thomas A. D'Amico,Malcolm M. DeCamp,Thomas J. Dilling,Jonathan E. Dowell,Scott N. Gettinger,Travis E. Grotz,Matthew A. Gubens,Aparna Hegde,Rudy P. Lackner,Michael Lanuti,Jules Lin,Billy W. Loo,Christine M. Lovly,Fabien Maldonado,Erminia Massarelli,Daniel Morgensztern,Thomas Ng,Gregory A. Otterson,Jose M. Pacheco,Sandip Pravin Patel,Gregory J. Riely,Jonathan W. Riess,Steven E. Schild,Theresa A. Shapiro,Aditi P. Singh,James P. Stevenson,Alda L. Tam,Tawee Tanvetyanon,Jane Yanagawa,Stephen C. Yang,Edwin Yau,Kristina M. Gregory,Miranda Hughes +41 more
TL;DR: Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer, and this selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastasis NSLI and actionable mutations.
References
More filters
Journal ArticleDOI
Principles of cancer screening: lessons from history and study design issues.
TL;DR: Although still inconsistently applied to early detection programs, policies, and belief systems in the United States, an evidence-based approach is essential to counteract the misleading--even potentially harmful--allure of intuition and individual observation.
Journal ArticleDOI
Screening for Hepatitis B Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement.
Douglas K Owens,Douglas K Owens,Karina W. Davidson,Alex H. Krist,Michael J. Barry,Michael D. Cabana,Aaron B. Caughey,Katrina E Donahue,Chyke A. Doubeni,John W. Epling,Martha Y. Kubik,Gbenga Ogedegbe,Lori Pbert,Michael Silverstein,Melissa A. Simon,Chien-Wen Tseng,John B. Wong +16 more
TL;DR: It is concluded with moderate certainty that screening for HCV infection in adults aged 18 to 79 years has substantial net benefit and is recommended for all asymptomatic adults without known liver disease.
Journal ArticleDOI
Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival.
TL;DR: To make inferences about the effectiveness of screening, the authors assessed mortality trends for squamous and adenocarcinoma in relation to incidence of these tumors, incidence of their precursors and survival.
Journal Article
Changes in the Leading Cause of Death: Recent Patterns in Heart Disease and Cancer Mortality.
TL;DR: The mortality burden of cancer has surpassed that of heart disease in several states and is now the leading cause of death for the non-Hispanic Asian or Pacific Islander and Hispanic populations.
Journal ArticleDOI
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
Alexander Tsodikov,Roman Gulati,Eveline A.M. Heijnsdijk,Paul F. Pinsky,Sue Moss,Sheng Qiu,Tiago M. de Carvalho,Jonas Hugosson,Christine D. Berg,Anssi Auvinen,Gerald L. Andriole,Monique J. Roobol,E. David Crawford,Vera Nelen,Maciej Kwiatkowski,Marco Zappa,Marcos Lujan,Arnauld Villers,Eric J. Feuer,Harry J. de Koning,Angela B. Mariotto,Ruth Etzioni +21 more
TL;DR: The objectives of this study were to formally test whether the effects of screening on prostate cancer mortality differed between the ERSPC and PLCO after differences in implementation and practice settings were accounted for and to estimate the effect of screening in both trials relative to no screening.